期刊
DRUG DISCOVERY TODAY
卷 24, 期 3, 页码 796-804出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.11.023
关键词
-
资金
- Science Foundation Ireland [12/RC/2275, 13/RP/B2549]
- European Regional Development Fund
The field of pharmaceutical cocrystals has reached a tipping point, particularly because cocrystals can improve the physicochemical properties of drugs without compromising their therapeutic benefit. Accounts of cocrystal investigations in the literature started in earnest in 2003 and patent applications soon followed. The frequency of both has steadily accelerated, demonstrating an enhanced understanding of the design, characterisation, and manufacture of cocrystals and heightened interest from industry. Indeed, there were four new product approvals from 2014 to 2017 and more are in the pipeline. Here, we review all marketed drug products that are based upon pharmaceutical cocrystal drug substances, starting with the first recorded example, Beta-Chlor (R) in 1963, with a particular emphasis on their discovery, rationale for use, and market impact.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据